Director, COO of Isis Pharmaceuticals Inc. (ISIS, Financial) B Lynne Parshall sells 7,090 shares of ISIS on 12/31/2009 at an average price of $11.21 a share.
Isis Pharmaceuticals, Inc. is a leading genomics-based drug discoveryand development company that is focused on RNA. RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research. The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services. Isis Pharmaceuticals Inc. has a market cap of $1.11 billion; its shares were traded at around $11.26 with and P/S ratio of 10.3.
ISIS is in the portfolios of Bruce Kovner of Caxton Associates.
Isis Pharmaceuticals, Inc. is a leading genomics-based drug discoveryand development company that is focused on RNA. RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research. The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services. Isis Pharmaceuticals Inc. has a market cap of $1.11 billion; its shares were traded at around $11.26 with and P/S ratio of 10.3.
ISIS is in the portfolios of Bruce Kovner of Caxton Associates.
CEO Recent Trades:
- Sell:: Chairman, President, CEO Stanley T Crooke sold 6,535 shares of ISIS stock on 12/30/2009 at the average price of 11.07, the price of the stock has increased by 1.72% since.
- Sell:: Chairman, President, CEO Stanley T Crooke sold 20,000 shares of ISIS stock on 12/22/2009 at the average price of 10.13, the price of the stock has increased by 11.15% since.
- Sell:: Chairman, President, CEO Stanley T Crooke sold 50,000 shares of ISIS stock on 12/16/2009 at the average price of 10.07, the price of the stock has increased by 11.82% since.
- Sell:: Chairman, President, CEO Stanley T Crooke sold 70,000 shares of ISIS stock on 12/14/2009 at the average price of 10.02, the price of the stock has increased by 12.38% since.
- Sell:: Chairman, President, CEO Stanley T Crooke sold 50,000 shares of ISIS stock on 12/09/2009 at the average price of 10.42, the price of the stock has increased by 8.06% since.
Directors and Officers Recent Trades:
- Sell:: Director, COO B Lynne Parshall sold 8,000 shares of ISIS stock on 12/30/2009 at the average price of 11.09, the price of the stock has increased by 1.53% since.
- Sell:: Director, COO B Lynne Parshall sold 26,910 shares of ISIS stock on 12/23/2009 at the average price of 10.42, the price of the stock has increased by 8.06% since.
- Sell:: Director, COO B Lynne Parshall sold 10,000 shares of ISIS stock on 12/15/2009 at the average price of 10.03, the price of the stock has increased by 12.26% since.
- Sell:: Senior Vice President C Frank Bennett sold 1,000 shares of ISIS stock on 12/15/2009 at the average price of 10.03, the price of the stock has increased by 12.26% since.
- Sell:: Director, COO B Lynne Parshall sold 23,000 shares of ISIS stock on 12/11/2009 at the average price of 10.08, the price of the stock has increased by 11.71% since.
